Our Mission
GLP-1 Education exists because the evidence base for GLP-1 receptor agonists is transformative, vast, and moves faster than most busy clinicians can keep up with.
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro), liraglutide (Victoza), and dulaglutide (Trulicity) — have substantially changed how type 2 diabetes and obesity are managed. Evidence from LEADER, SUSTAIN-6, SELECT, STEP 1–5, SURPASS 1–5, PIONEER, and FLOW continues to evolve rapidly, with next-generation dual and triple agonists in Phase 3.
Comprehensive, unbiased GLP-1 education is hard to find — evidence is scattered across SmPCs, NICE guidelines, trial publications, and specialist conferences.
This is an independent educational resource, freely accessible to any clinician, student, or interested reader. All content is referenced against published clinical guidelines and peer-reviewed literature. It is not affiliated with, or endorsed by, any NHS organisation, pharmaceutical company, or regulatory body.
Evidence-Based Content
Every module grounded in current peer-reviewed literature and clinical guidelines, reviewed quarterly to stay current.
Expert Faculty
Content authored by practising clinicians including endocrinologists, diabetes specialists, GPs, and pharmacists.
Supports CPD Learning
Content is designed to support continuing professional development. Clinicians should verify formal CPD accreditation requirements with their own regulatory body.
Our Values
Every claim traceable to a peer-reviewed source. No sponsored content, no promotional bias.
Free to every clinician, student, and patient. No subscription, no paywall, no hidden cost.
Reviewed quarterly and updated within days of major guideline changes or landmark trial publication.
Every educational decision anchored in improving patient outcomes, not professional prestige.
Developed and reviewed by practicing clinicians with expertise in diabetes, metabolic medicine, and pharmacology.
No pharmaceutical funding influences our content. Completely independent editorial process.
Content Team
This resource is developed by practising clinicians with expertise in diabetes, metabolic medicine, pharmacology, and primary care. Individual names are not published; content is attributed by clinical specialty only.
{{ member.specialty }}
{{ member.bio }}
Disclaimer: This is an independent educational resource. It is not affiliated with, endorsed by, or recognised by NHS England, NICE, the GMC, GPhC, NMC, RCGP, EMA, or MHRA. Content is for educational purposes only and does not constitute clinical advice. Always refer to current SmPCs, NICE guidelines, and local formularies for prescribing decisions.
Content referenced against published clinical guidelines and regulatory documentation